Abivax S.A.
ABVX
Kedudukan dalam Saham
#2417
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Harga Saham
$91.47
Modal Pasaran
$7.98B
Perubahan (1 hari)
-3.44%
Perubahan (1 tahun)
3.51%
Negara
FR
Perdagangan Abivax S.A. (ABVX)
Kategori
Healthcare
Pendapatan untuk Abivax S.A. (ABVX)
Pendapatan pada Jun 2026 TTM: $-399.84M
Menurut laporan kewangan terkini Abivax S.A., pendapatan semasa syarikat ialah $-399.84M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-190.31M, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $-168.29M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Abivax S.A. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-399.84M | 2.24% |
| 2025 | $-391.07M | 105.49% |
| 2024 | $-190.31M | 13.09% |
| 2023 | $-168.29M | 140.56% |
| 2022 | $-69.96M | 35.02% |
| 2021 | $-51.81M | 6.02% |
| 2020 | $-48.87M | 24.83% |
| 2019 | $-39.15M | 72.11% |
| 2018 | $-22.75M | 36.24% |
| 2017 | $-16.70M | -10.99% |
| 2016 | $-18.76M | -8.06% |
| 2015 | $-20.40M | 229.39% |
| 2014 | $-6.19M | -40.41% |
| 2013 | $-10.39M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,419.26% |
US
|
|
| $-3.09B | 672.06% |
US
|
|
| $-4.02B | 904.46% |
AU
|
|
| $3.01B | -851.74% |
BE
|
|
| $1.95B | -587.86% |
NL
|
